HK Stock Market Move | KEYMED BIO-B(02162) has increased by nearly 6%. The acquisition agreement of Ouro Medicines has been completed. The company has received an initial payment of $257 million.

KEYMED BIO-B (02162) rose nearly 6%, reaching 4.95% as of the time of writing, to HK$58.3, with a trading volume of HK$70.1441 million. On the news front, recently, KEYMED BIO-B announced the sale of a minority stake in Ouro Medicines by the Group. On June 5, 2026, the Group's NewCo joint venture with Ouro Medicines, as disclosed in the merger agreement, has now been officially completed, with the Group receiving a down payment of $257 million. Under the terms of the merger agreement, Gilead has acquired all of Ouro Medicines' shares for $1.675 billion in down payment and up to $500 million in potential milestone payments. The Group has been informed that under the arrangement between Gilead Sciences Inc. and Lakefront Biotherapeutics NV (Lakefront, Euronext & Nasdaq: LKFT, formerly known as Galapagos), both parties will share the down payment (adjusted as customary) and up to $500 million in potential milestone payments. As a shareholder of Ouro Medicines, the Group has received a down payment of approximately $257 million and has the right to receive up to approximately $70 million in milestone payments. In addition, the exclusive license agreement entered into between the Group and Ouro Medicines in November 2024 remains valid, with up to $610 million in milestone payments and tiered royalties on sales to be fulfilled by Gilead and Lakefront.